drugset / Trial / NCT00034125

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125

Phase 3 Completed Eli Lilly and Company
RandomizedSingle-groupDouble-blindTreatment

Summary

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule
Subject arzoxifene Other / unclassified

Indications